Novartis pays $85m to shed Array, and other recent brush offs
This article was originally published in Scrip
Array BioPharma has joined an assortment of companies that have lost their big pharma partners in recent days. Array has been relinquished by Novartis, Dynavax discarded by GlaxoSmithKline, Grünenthal abandoned by Actavis, and Pozen deserted by Sanofi, all in the past week.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.